Genetic testing can be targeted cancer therapy
Scientists have found a way to identify patients with breast cancer are likely to respond to a type of chemotherapy. The new test also predict that is unlikely to see the benefit of treatment and help save unnecessary side effects.
The results – presented by researchers at the European Cancer Conference in Spain – that doctors should be able to tailor treatment to patients who will benefit and avoid the administration of toxic drugs to those who are not rescued.
As part of the consideration of four large studies of breast cancer, researchers have discovered an abnormality on chromosome 17, called CEP17 is an indicator of “very important” that the tumor response to chemotherapy with anthracyclines resource.
Personalized medicine
Anthracyclines are antitumor antibiotics that interfere with enzymes involved in DNA replication. They are widely used against a variety of cancers.
Researchers have found that if patients were treated with anthracycline-based CEP17 were about two-thirds more likely to survive and survive without cancer recurrence than those not treated with anthracyclines.
The results provide more tools for personalized medicine physicians a reality in personalized cancer treatment. CEP17 is on the same chromosome as other known genes involved in breast cancer HER-2, and can be detected by a simple test.
The researchers say that the existence of a proof of the ease of access to immediate medical CEP17 means to begin chemotherapy to better meet patient needs.
They say the extra work in CEP17 is needed to see if I could say more about breast cancer.
“CEP17 functions as a biomarker for predicting response to anthracyclines, but do not know why it works,” says Bartlett.
“Our next step is to identify and treat cancers that do not behave as markers do.”
Incoming search terms:
- genetic testing for cancer respond to chemotherapy
- genetic testing for targeted chemotherapy
